Table 2.
In vivo and clinical trials synergistic effects between PPARγ ligands and other agents. Descriptions reflect most noteworthy finding of each study.
| Platinum-based compounds | Taxanes | Topoisomerase inhibitors | Anti-metabolites | |
|---|---|---|---|---|
| Rosiglitazone | (i) ↓ Volume of A549 NSCLC xenografted tumours [31] | |||
| (ii) ↓ Volume in KRAS- and EGFRdriven lung tumours without disrupting immune system [57] | ||||
| (iii) ↓ Volume and ↑ differentiation of DMBA-induced breast tumours; treatment minimized nephrotoxicity [32] *pre-treatment | ||||
|
| ||||
| Troglitazone | (i) ↓ Volume and ↑ overall survival of EHMES-10 malignant pleural mesothelioma xenografted tumours [34] | |||
|
| ||||
| Pioglitazone |
Phase 2 clinical trial:
(i) 30% of patients with high grade gliomas experienced disease stabilization; treatment well tolerated by all [58] |
|||
|
| ||||
| RS5444 | (i) ↓ Volume of DRO90-1 and ARO81 anaplastic thyroid carcinoma xenografted tumours [53] | |||
|
| ||||
| 15d-PGJ2 | (i) ↓ Volume of A549 and H460 NSCLC xenografted tumours [54] | |||
|
| ||||
| LY 293111 |
Phase 1 clinical trial: (i) ↓ GI toxicity in patients with advanced solid tumours [59] |
(i) ↓ Volume of S2-013 pancreatic xenografted tumours; minimized side effects [60] | ||